載入...
Recent US Food and Drug Administration Warnings on Hepatitis B Reactivation With Immune-Suppressing and Anticancer Drugs: Just the Tip of the Iceberg?
Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe and potentially fatal. The US Food and Drug Administration has recently drawn attention to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti-CD20 agents ofatumumab or rituximab....
Na minha lista:
| 發表在: | Hepatology |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497492/ https://ncbi.nlm.nih.gov/pubmed/25412906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27609 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|